Clinical Trial Update: Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of lenalidomide in relapsed or refractory chronic lymphocytic leukemia completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-10-02